Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
12:00am, Friday, 07'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference
08:05pm, Tuesday, 04'th Aug 2020
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming Canaccord Genuity 40th Annual Growth Conferenc
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
04:31pm, Monday, 03'rd Aug 2020
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme To Host Second Quarter 2020 Financial Results Webcast And Conference Call
08:05pm, Wednesday, 29'th Jul 2020
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2020 on Monday, August 10 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, presiden
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
04:32pm, Tuesday, 28'th Jul 2020
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Bonanza - Second Half Outlook
08:24am, Tuesday, 28'th Jul 2020
Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre
Should You Take Comfort From Insider Transactions At Halozyme Therapeutics, Inc. (NASDAQ:HALO)?
01:49pm, Thursday, 23'rd Jul 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Halozyme Therapeutics (NASDAQ:HALO) Downgraded by BidaskClub
05:38am, Saturday, 18'th Jul 2020
BidaskClub lowered shares of Halozyme Therapeutics (NASDAQ:HALO) from a strong-buy rating to a buy rating in a research report released on Tuesday morning, BidAskClub reports. HALO has been the subjec
Did Hedge Funds Make The Right Call On Halozyme Therapeutics, Inc. (HALO) ?
05:30pm, Friday, 17'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Drug Stock May Be Overdue for a Short Squeeze
06:46pm, Thursday, 09'th Jul 2020
Halozyme Therapeutics flashed a bull signal that could push the security to fresh record highs
AQR Capital Management LLC Sells 33,804 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
06:58am, Saturday, 04'th Jul 2020
AQR Capital Management LLC trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.6% in the first quarter, according to its most recent Form 13F filing with the Securities and
Investors Buy High Volume of Halozyme Therapeutics Put Options (NASDAQ:HALO)
01:10am, Saturday, 04'th Jul 2020
Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the target of unusually large options trading activity on Thursday. Traders bought 417 put options on the stock. This is an increase of approximately 522%
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 1)
AbbVie Inc (NYSE: ABBV)
ADC...
Halozyme Therapeutics: Enhanced Prospects, Expensive Valuations
05:26pm, Tuesday, 30'th Jun 2020
Halozyme Therapeutics is an expensive stock that’s been living on its long-term loans. But it has a very exciting future. Janssen Biotech, its partner, has rece
